echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Beihai Kangcheng's clinical trial application for the treatment of Gaucher's disease CAN103 new drug approved in China

    Beihai Kangcheng's clinical trial application for the treatment of Gaucher's disease CAN103 new drug approved in China

    • Last Update: 2021-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Beijing, China and Cambridge, Massachusetts, U.


    Dr.


    About Gaucher disease (GD)

    Gaucher disease is one of the most common lysosomal storage diseases.


    About Beihai Kangcheng Pharmaceutical Co.


    Beihai Kangcheng Pharmaceutical Co.


    Beihai Kangcheng has a comprehensive and differentiated pipeline composed of 13 pharmaceutical assets with huge market potential, targeting some of the most common rare diseases and rare tumors


    These diseases include Hunter syndrome (MPS II) and other lysosomal storage diseases (LSD), complement-mediated diseases, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, and glial Blastoma (GBM)


    Beihai Kangcheng strategically combines global cooperation with internal research to establish a diversified drug portfolio, while investing in the next generation of gene therapy technology for rare disease treatment


    For more information about Beihai Kangcheng Pharmaceutical Co.


    Source: Beihai Kangcheng

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.